Retrieve available abstracts of 37 articles: HTML format
Single Articles
June 2025
BUMA AIG, Muntinghe-Wagenaar MB, van der Noort V, de Vries R, et al Reply to Letter to the Editor "Lung cancer detection by electronic nose analysis
of exhaled breath: a multi-center prospective external validation study" by Liu
et al., G. Rocco, and Szarpak et al.
Ann Oncol. 2025 Jun 2:S0923-7534(25)00198-X. doi: 10.1016/j.annonc.2025. PubMed
RIEDL JM, Fece de la Cruz F, Lin JJ, Parseghian C, et al Genomic landscape of clinically acquired resistance alterations in patients
treated with KRAS(G12C) inhibitors.
Ann Oncol. 2025;36:682-692. PubMedAbstract available
May 2025
DE MARINIS F, Kim TM, Bonanno L, Cheng S, et al Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated
advanced non-small cell lung cancer with MET overexpression and/or amplification
following disease progression on osimertinib: primary results from the phase II
SAVANNAH s
Ann Oncol. 2025 May 22:S0923-7534(25)00157-7. doi: 10.1016/j.annonc.2025. PubMedAbstract available
LIU J, Shi Y, Yang Y Letter Re: Lung cancer detection by electronic nose analysis of exhaled breath: a
multi-center prospective external validation study.
Ann Oncol. 2025 May 12:S0923-7534(25)00195-4. doi: 10.1016/j.annonc.2025. PubMed
SZARPAK L, Pruc M, Bizon M, Olszewski M, et al Validation Study of Electronic Nose Detection for Lung Cancer.
Ann Oncol. 2025 May 12:S0923-7534(25)00197-8. doi: 10.1016/j.annonc.2025. PubMed
ROCCO G Letter to the Editor: Comments on the study of lung cancer detection by
electronic nose analysis of exhaled breath.
Ann Oncol. 2025 May 12:S0923-7534(25)00196-6. doi: 10.1016/j.annonc.2025. PubMed
FELIP E, Popat S, Dafni U, Ribi K, et al A randomised phase III study of bevacizumab and carboplatin-pemetrexed
chemotherapy with or without atezolizumab as first-line treatment for advanced
pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trial.
Ann Oncol. 2025;36:548-560. PubMedAbstract available
March 2025
BUMA AIG, Muntinghe-Wagenaar MB, van der Noort V, de Vries R, et al Lung cancer detection by electronic nose analysis of exhaled breath: a
multi-center prospective external validation study.
Ann Oncol. 2025 Mar 31:S0923-7534(25)00125-5. doi: 10.1016/j.annonc.2025. PubMedAbstract available
FELIP E, Rojas CI, Schenker M, Kowalski DM, et al Subcutaneous Versus Intravenous Pembrolizumab, in Combination With Chemotherapy,
for Treatment of Metastatic Non-Small Cell Lung Cancer: The Phase 3 3475A-D77
Trial.
Ann Oncol. 2025 Mar 25:S0923-7534(25)00123-1. doi: 10.1016/j.annonc.2025. PubMedAbstract available
DI FEDERICO A, Hong L, Elkrief A, Thummalapalli R, et al Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune
microenvironment characterization and outcomes to immunotherapy-based treatments
and KRAS(G12C) inhibitors.
Ann Oncol. 2025;36:297-308. PubMedAbstract available
January 2025
REMON J, Saw SPL Teliso-V and osimertinib: the METamorphosis of EGFR-mutant lung cancer?
Ann Oncol. 2025 Jan 22:S0923-7534(25)00012-2. doi: 10.1016/j.annonc.2025. PubMed
HORINOUCHI H, Cho BC, Camidge DR, Goto K, et al Results from a phase 1b study of telisotuzumab vedotin in combination with
osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally
advanced/metastatic non-small cell lung cancer (NSCLC) after progression on prior
osimertinib.
Ann Oncol. 2025 Jan 11:S0923-7534(25)00005-5. doi: 10.1016/j.annonc.2025. PubMedAbstract available
November 2024
FELIP E, Cho BC, Nguyen D, Curtin JC, et al Reply to the Letter to the Editor regarding 'PFS, OS or toxicity: what is the
most important factor in the treatment of EGFR-mutated lung cancer?' by T.
Nishimura and H. Fujimoto.
Ann Oncol. 2024 Nov 8:S0923-7534(24)04060-2. doi: 10.1016/j.annonc.2024. PubMed
October 2024
MEYER ML, Peters S, Mok TS, Lam S, et al Lung Cancer Research and Treatment: Global Perspectives and Strategic Calls to
Action.
Ann Oncol. 2024 Oct 14:S0923-7534(24)04055-9. doi: 10.1016/j.annonc.2024. PubMedAbstract available
NISHIMURA T, Fujimoto H PFS, OS or toxicity: What is the most important factor in the treatment of
EGFR-mutated lung cancer?
Ann Oncol. 2024 Oct 11:S0923-7534(24)04059-6. doi: 10.1016/j.annonc.2024. PubMed
HARRIS E, Taflin NF, Chitkara A, Tagliamento M, et al Time to rethink platinum choices in the era of immunotherapy in lung cancer.
Ann Oncol. 2024 Oct 10:S0923-7534(24)04058-4. doi: 10.1016/j.annonc.2024. PubMed
JOHN A, McDonald F, Popat S Inoperable Stage III EGFR Mutant Non-Small Cell Lung Cancer: time for drug first,
local later?
Ann Oncol. 2024 Oct 10:S0923-7534(24)04054-7. doi: 10.1016/j.annonc.2024. PubMed
September 2024
LU S, Ahn MJ, Reungwetwattana T, Ozguroglu M, et al Osimertinib after definitive chemoradiotherapy in unresectable stage III
epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of
central nervous system efficacy and distant progression from the phase III LAURA
study.
Ann Oncol. 2024 Sep 11:S0923-7534(24)03823-7. doi: 10.1016/j.annonc.2024.08.2243 PubMedAbstract available
June 2024
DI FEDERICO A, Alden SL, Smithy JW, Ricciuti B, et al Intrapatient variation in PD-L1 expression and tumor mutational burden and the
impact on outcomes to immune checkpoint inhibitor therapy in patients with
non-small cell lung cancer.
Ann Oncol. 2024 Jun 29:S0923-7534(24)00745-2. doi: 10.1016/j.annonc.2024. PubMedAbstract available
FELIP E, Cho BC, Gutierrez V, Alip A, et al Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced
non-small-cell lung cancer with biomarkers of high-risk disease: a secondary
analysis from MARIPOSA.
Ann Oncol. 2024 Jun 26:S0923-7534(24)00702-6. doi: 10.1016/j.annonc.2024. PubMedAbstract available
May 2024
SCOTT S, Levy B New ADCs bring new questions in EGFR NSCLC and beyond.
Ann Oncol. 2024;35:412-413. PubMed
YU HA, Baik C, Kim DW, Johnson ML, et al Translational insights and overall survival in the U31402-A-U102 study of
patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC.
Ann Oncol. 2024;35:437-447. PubMedAbstract available
April 2024
PETERS S, Loi S, Andre F, Chandarlapaty S, et al Antibody-drug conjugates in lung and breast cancer: Current evidence and future
directions - a position statement from the ETOP IBCSG Partners Foundation.
Ann Oncol. 2024 Apr 20:S0923-7534(24)00108-X. doi: 10.1016/j.annonc.2024. PubMedAbstract available
March 2024
MOIK F, Riedl JM, Ay C Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in
EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary
results from the phase III MARIPOSA-2 study.
Ann Oncol. 2024;35:327. PubMed
PASSARO A, Wang J, Shah S, Bauml JM, et al Letter to the Editor regarding 'Correspondence to: Amivantamab plus chemotherapy
with and without lazertinib in EGFR-mutant advanced NSCLC after disease
progression on osimertinib: primary results from the phase III MARIPOSA-2 study'
by Moik F, Riedl
Ann Oncol. 2024;35:328-329. PubMed
February 2024
ROLFO C, Russo A Navigating into a stormy sea: liquid biopsy enters peri-operative management in
early-stage non-small cell lung cancer.
Ann Oncol. 2024;35:147-149. PubMed
January 2024
SANTUCCI C, Mignozzi S, Malvezzi M, Boffetta P, et al European cancer mortality predictions for the year 2024 with focus on colorectal
cancer.
Ann Oncol. 2024 Jan 17:S0923-7534(23)05110-4. doi: 10.1016/j.annonc.2023. PubMedAbstract available
BUROTTO M, Zvirbule Z, Mochalova A, Runglodvatana Y, et al Corrigendum to 'IMscin001 Part 2: a randomised phase III, open-label, multicentre
study examining the pharmacokinetics, efficacy, immunogenicity, and safety of
atezolizumab subcutaneous versus intravenous administration in previously treated
locally a
Ann Oncol. 2024 Jan 8:S0923-7534(23)05112-8. doi: 10.1016/j.annonc.2023. PubMed
PASSARO A, Wang J, Wang Y, Lee SH, et al Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced
NSCLC after disease progression on osimertinib: primary results from the phase
III MARIPOSA-2 study.
Ann Oncol. 2024;35:77-90. PubMedAbstract available
PRELAJ A, Miskovic V, Zanitti M, Trovo F, et al Artificial intelligence for predictive biomarker discovery in immuno-oncology: a
systematic review.
Ann Oncol. 2024;35:29-65. PubMedAbstract available
December 2023
FULTON-WARD T, Middleton G The impact of genomic context on outcomes of solid cancer patients treated with
genotype-matched targeted therapies: a comprehensive review.
Ann Oncol. 2023;34:1113-1130. PubMedAbstract available
November 2023
TRAN HT, Heeke S, Sujit S, Vokes N, et al Circulating tumor DNA and radiological tumor volume identify patients at risk for
relapse with resected, early-stage non-small cell lung cancer.
Ann Oncol. 2023 Nov 20:S0923-7534(23)05072-X. doi: 10.1016/j.annonc.2023. PubMedAbstract available
SHIRAISHI Y, Sekino Y, Horinouchi H, Ohe Y, et al High incidence of cytokine release syndrome in patients with advanced NSCLC
treated with nivolumab plus ipilimumab.
Ann Oncol. 2023;34:1064-1065. PubMed
October 2023
BORGHAEI H, de Marinis F, Dumoulin D, Reynolds C, et al SAPPHIRE: Phase III Study of Sitravatinib Plus Nivolumab Versus Docetaxel in
Advanced Non-Squamous Non-Small Cell Lung Cancer.
Ann Oncol. 2023 Oct 11:S0923-7534(23)04019-X. doi: 10.1016/j.annonc.2023. PubMedAbstract available
JOHN A, Popat S Adjuvant immune checkpoint inhibitor therapy for resected non-small-cell lung
cancer: dessert, starters, or a sandwich?
Ann Oncol. 2023;34:829-830. PubMed
GOUDA MA, Hu MI, Cabanillas ME, Wu J, et al Weight gain in patients with RET aberrant cancers treated with brain penetrant
RET selective inhibitors.
Ann Oncol. 2023;34:946-948. PubMed
August 2023
BESSE B, Felip E, Campelo RG, Cobo M, et al Randomized Open-Label Controlled Study of Cancer Vaccine OSE2101 Versus
Chemotherapy in HLA-A2-positive Patients with Advanced Non-Small Cell Lung Cancer
with Resistance to Immunotherapy: ATALANTE-1.
Ann Oncol. 2023 Aug 1:S0923-7534(23)00790-1. doi: 10.1016/j.annonc.2023. PubMedAbstract available